Olema Pharmaceuticals, Inc.
OLMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001750284
In the last 90 days, Olema Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 185 institutions reported holding it in 13F filings for Q2 2026, worth $1.28B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Olema Pharmaceuticals, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 200
- +75 vs. Q3 2025
- Shares held
- 90.7M
- +22.4M (+32.9%) vs. Q3 2025
- Total value
- $2.27B
- +$1.60B (+239.4%) vs. Q3 2025
- New holders
- 87
- 55 more added
- Sold out
- 12
- 39 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OLMA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 185 | $1.28B |
| Q1 2026 | 195 | $1.51B |
| Q4 2025 | 200 | $2.27B |
| Q3 2025 | 126 | $668.2M |
| Q2 2025 | 123 | $300.5M |
| Q1 2025 | 134 | $248.0M |
| Q4 2024 | 157 | $415.4M |
| Q3 2024 | 130 | $700.3M |
| Q2 2024 | 129 | $626.9M |
| Q1 2024 | 126 | $635.2M |
| Q4 2023 | 113 | $717.1M |
| Q3 2023 | 97 | $584.4M |
| Q2 2023 | 87 | $329.2M |
| Q1 2023 | 66 | $116.1M |
| Q4 2022 | 67 | $81.6M |
| Q3 2022 | 73 | $92.1M |
| Q2 2022 | 76 | $139.2M |
| Q1 2022 | 91 | $155.2M |
| Q4 2021 | 97 | $359.5M |
| Q3 2021 | 76 | $1.01B |
| Q2 2021 | 69 | $1.05B |
| Q1 2021 | 74 | $1.16B |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Olema Pharmaceuticals, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 0 | $0 | 0.00% | −3,470,172−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −250,000−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −35,179−100.0% | Sold out |
| Zacks Investment Management | 0 | $0 | 0.00% | −30,803−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −45,842−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −21,100−100.0% | Sold out |
| Titleist Asset Management, LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −13,500−100.0% | Sold out |
| Sender Co & Partners, Inc. | 0 | $0 | 0.00% | −10,793−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −10,299−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −1,707−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −466−100.0% | Sold out |
| Point72 Europe (London) LLP | – | – | – | – | Not filed |